SYNERGISTIC ENHANCEMENT OF MITOGEN RESPONSES OF HUMAN-LYMPHOCYTES BY INHIBITORS OF CYCLOOXYGENASE AND 5,8,11-EICOSATRIYNOIC ACID, AN INHIBITOR OF 12-LIPOXYGENASE AND LEUKOTRIENE BIOSYNTHESIS

被引:10
作者
BLOMGREN, H
HAMMARSTROM, S
WASSERMAN, J
机构
[1] KAROLINSKA INST, DEPT MED CHEM 2, S-10401 STOCKHOLM 60, SWEDEN
[2] STOCKHOLM CTY COUNCIL, CENT MICROBIOL LAB, STOCKHOLM, SWEDEN
来源
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY | 1987年 / 83卷 / 03期
关键词
D O I
10.1159/000234304
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Blood mononuclear cells are well-known producers of various cyclo-oxygenase and lipoxygenase metabolites of arachidonic acid, some of which possess immunoregulatory functions. In the present investigation, we have examined 3H-thymidine incorporation in human blood lymphocytes cultured with polyclonal mitogens and antigens in the presence of various inhibitors of cyclo-oxygenase (such as indomethacin and meclofenamic acid) and an inhibitor of 12-lipoxygenase and leukotriene biosynthesis, 5,8,11-eicosatriynoic acid (ETI). It was observed that these inhibitors could augment mitogen responses of nonpurified lymphocyte preparations but not of preparations which were depleted of monocytes. The results indicate that monocytes and not lymphocytes were the main producers of immunosuppressive eicosanoids derived from arachidonic acid. Further, mitogenic responses in the presence of both an inhibitor of cyclo-oxygenase and ETI were augmented to a higher extent than expected. Again, this enhancement was not observed in preparations depleted of monocytes. Arachidonic acid metabolism was examined in mitogen-stimulated cultures pulsed with 14C-arachidonic acid. It was observed that the production of three metabolites was inhibited by meclofenamic acid, whereas the amounts of another 14Cr-labeled compound was almost doubled in the presence of meclofenamic acid.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 31 条
  • [1] BANKHURST AD, 1981, J LAB CLIN MED, V97, P179
  • [2] BLOOD LYMPHOCYTE POPULATION 4 TO 6 YEARS AFTER ADJUVANT CYCLIC CHEMOTHERAPY FOR OPERABLE BREAST-CARCINOMA
    BLOMGREN, H
    ROTSTEIN, S
    PETRINI, B
    WASSERMAN, J
    [J]. ACTA RADIOLOGICA ONCOLOGY, 1985, 24 (02): : 123 - 127
  • [3] BLOMGREN H, 1974, SCAND J IMMUNOL, V3, P655, DOI 10.1111/j.1365-3083.1974.tb01299.x
  • [4] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [5] PROSTAGLANDIN GENERATION BY SEPARATED HUMAN-BLOOD MONONUCLEAR CELL-FRACTIONS
    BRAY, MA
    POWELL, RG
    LYDYARD, PM
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1981, 3 (04): : 377 - 381
  • [6] DEMBINSKAKIEC A, 1976, ADV PROSTAG THROMB R, V1, P99
  • [7] PROSTAGLANDIN (PG) RELEASE IN THE MIXED LYMPHOCYTE CULTURE - EFFECT OF PRESENSITIZATION BY A SKIN ALLOGRAFT - NATURE OF THE PG-PRODUCING CELL
    DY, M
    ASTOIN, M
    RIGAUD, M
    HAMBURGER, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1980, 10 (02) : 121 - 126
  • [8] FISCHER A, 1981, J IMMUNOL, V126, P1452
  • [9] SELECTIVE FEEDBACK INHIBITION OF THE 5-LIPOXYGENATION OF ARACHIDONIC-ACID IN HUMAN T-LYMPHOCYTES
    GOETZL, EJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1981, 101 (02) : 344 - 350
  • [10] Goldyne M., 1983, Recent advances in clinical immunology, P9